Inadequate Glycemic Control In Type 1 Diabetes:
Why Can We Not Achieve Glycemic Targets?

Course Description

This interactive web activity provides an update on the need for non-insulin adjunctive treatments for type 1 diabetes (T1D). The activity reviews the challenges of managing glycemic levels in people with T1D, limitations of insulin therapy, and need for effective adjunctive treatments.

Target Audience

This activity has been designed to meet the educational needs of endocrinologists and other healthcare professionals involved in the diagnosis, treatment, or management of patients with T1D.


Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Review the potential barriers to care, associated risks, and impact of unachieved glycemic control in patients with Type 1 diabetes.
  • Describe currently available adjunctive options for glycemic control.
  • Discuss the mechanisms of action and potential synergistic effects of new and emerging sodium-glucose cotransporter (SGLT) 1 and 2 inhibitors.

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:

Faculty Relationship Identified With:
Satish K. Garg, MD Consultant/Advisor:Eli Lilly and Company, Medtronic, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Lexicon Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi, Mannkind Corporation, Senseonics, and Zealand Pharma A/S.
*Grant/Research Support:Animas Corporation, DarioHealth Corp., Dexcom, Eli Lilly and Company, JDRF, Lexicon Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, Novo Nordisk A/S, T1D Exchange, and Sanofi.
 

*All Research grants through University of Colorado Denver

Non-faculty

Sandy Breslow, Alison Kemp, Bernard M. Abrams, MD, Marilu Kelly, MSN, RN, CNE, Louis Settembrino, CHCP, and Christina M. Ohnsman, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier, and Catalyst Medical Education, LLC.

  

CME CREDIT (PHYSICIANS)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE CREDIT (NURSES)

This continuing nursing education activity, provided by Elsevier, awards 0.75 contact hour for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.



CME/CE INQUIRIES/SPECIAL NEEDS

For all CME/CE inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, Catalyst Medical Education, LLC., and Sanofi US and Lexicon Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of participation

In order to claim credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Nurses who attain a grade of 70% on the post-activity test question and who complete the evaluation before the expiration date will receive a certificate of completion for 0.75 contact hour. There is no partial credit will be awarded for this activity.
  6. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  7. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Release date: October 31, 2018
Expiration date: October 31, 2019